| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-10-10 | Millenium Pharmaceuticals (USA - MA), wholly owned subsidiary of Takeda Pharmaceutical (Japan) Crescendo Biologics (UK) | Humabody® -based therapeutics | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2016-10-10 | Bone Therapeutics (Belgium) | resignation |
Bone diseases - Regenerative medicine | Resignation | ||
| 2016-10-07 | AstraZeneca (UK) Cilag GmbH International, a J&J company (USA - NJ) | Rhinocort Aqua® (budesonide) | allergic rhinitis, non-allergic rhinitis | product acquisition |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Product acquisition |
| 2016-10-07 | Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) (USA) Sanofi (France) | Leukine® (sargramostim) | acute radiation syndrome | services contract |
Hematological diseases | Services contract |
| 2016-10-07 | Eli Lilly (USA - IN) National Cancer Institute (NCI) (USA) | National Cancer Institute's Blood Profiling Atlas | collaboration | Cancer - Oncology | Collaboration agreement | |
| 2016-10-06 | Molecular Partners (Switzerland) Janssen Biotech (J&J company - USA) | multispecific DARPins® including multi-DARPin® drug candidate targeting IL-13 & IL-17 | undisclosed immunological diseases | R&D
|
Immunological diseases | Termination of an agreement |
| 2016-10-06 | Oramed Pharmaceuticals (Israel) Hefei Tianhui Incubation of Technologies HTIT (China) | ORMD-0801 | licensing - investment | Metabolic diseases | Milestone | |
| 2016-10-06 | PX’Therapeutics, a subsidiary of the Aguettant group (France) Relief Therapeutics (Switzerland) | atexakin alfa | peripheral diabetic neuropathy | production manufacturing |
Metabolic diseases - Neurological diseases | Production agreement |
| 2016-10-06 | Teva Pharmaceutical Industries (Israel) Celltrion Healthcare (South Korea) | CT-P10 (biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® ) CT-P6 (biosimilar trastuzumab - biosimilar version of trastuzumab - Herceptin® | non-Hodgkin's lymphoma, chronic lymphocytic leukemia lheumatoid Arthritis (RA), Wegener's Granulomatosis and Microscopic Polyangiitis (MPA) | commercialisation |
Cancer - Oncology - Rare diseases - Autoimmune diseases - Rheumatic diseases | Commercialisation agreement |
| 2016-10-06 | Merck KGaA (Germany) | M Lab™ Collaboration Center in Incheon | opening of new premises | Technology - Services | Opening of new premises | |
| 2016-10-06 | Arrowhead Research Corporation (USA - CA) Spring Bank Pharmaceuticals (USA - MA) | ARC-520 and SB 9200 | chronic hepatitis B | clinical research |
Infectious diseases | Clinical research agreement |
| 2016-10-06 | Orchard Therapeutics (UK) | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | ||
| 2016-10-06 | Gemphire Therapeutics (USA - Mich) | nomination | Liver diseases - Hepatic diseases | Nomination | ||
| 2016-10-05 | Daiichi Sankyo (Japan) Medicines for Malaria Venture | antimalarial drug | malaria | R&D |
Parasitic diseases | R&D agreement |
| 2016-10-05 | AstraZeneca (UK) Insmed (USA - MA) | AZD7986, now INS1007 | non-cystic fibrosis bronchiectasis | licensing |
Lung diseases - Respiratory diseases | Licensing agreement |
| 2016-10-05 | Anavex Life Sciences (USA - NY) Ariana Pharma (France) | KEM® (Knowledge, Extraction, Management) patient stratification technology | Alzheimer's disease | collaboration |
Neurodegenerative diseases | Collaboration agreement |
| 2016-10-04 | Daiichi Sankyo (Japan) Agonox (US - OR) | undisclosed immuno-oncology target | collaboration |
Cancer - Oncology | Collaboration agreement | |
| 2016-10-04 | Sarepta Therapeutics (USA - MA) Summit Therapeutics (UK) | utrophin modulator pipeline including ezutromid | Duchenne muscular dystrophy | licensing R&D |
Rare diseases - Genetic diseases - Neuromuscular diseases | Licensing agreement |
| 2016-10-04 | Seattle Genetics (USA - WA) | nomination |
Nomination | |||
| 2016-10-04 | Santhera Pharmaceuticals (Switzerland) | nomination |
Nomination |
